Premium
Wfs1 mutation makes mice more susceptible to metabolic changes caused by antipsychotics
Author(s) -
Toots Maarja,
Narvik Jane,
Ottas Aigar,
Plaas Mario,
Vasar Eero
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.1014.1
Subject(s) - antipsychotic , olanzapine , wolfram syndrome , metabolic syndrome , mutation , endocrinology , haloperidol , diabetes mellitus , medicine , atypical antipsychotic , metabolic disorder , type 2 diabetes , gene , schizophrenia (object oriented programming) , genetics , biology , psychiatry , dopamine
Mutations in WFS1 gene cause autosomal recessive disorder Wolfram syndrome (WS). While homozygous mutations in Wfs1 cause WS, studies have shown that heterozygous Wfs1 mutation carriers have increased risk for psychiatric disorders, type 2 diabetes and metabolic syndrome. Therefore, in this study, the effect of chronic administration of haloperidol (first generation antipsychotic) and olanzapine (second generation antipsychotic) on different metabolic parameters was investigated, using targeted mass‐spectrometry. Results show that heterozygous Wfs1 mutation mice have changes in their metabolism and are more receptive to changes caused by antipsychotics, which may indicate increased susceptibility to metabolic syndrome accompanying antipsychotic treatment.